Across TCGA pan-cancer cohorts, DEDD Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DEDD data layer compared with 26 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in thymoma (THYM), where higher DEDD Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DEDD expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.
THYM, SCLC, and UCEC are the cancer types where DEDD Mutation most reproducibly stratifies survival.